This study compared the effects of low-flow sevoflurane, high-flow sevoflurane and low-flow isoflurane on hepatorenal function during and after more than 10 hours of anaesthesia. Twenty-five patients scheduled for elective orthopaedic surgery were categorized into three groups; low-flow sevoflurane (fresh gas flow at 1 litre/min, n=9), highflow sevoflurane (5 l/min, n=7), or low-flow isoflurane (1 l/min, n=9). Inspiratory compound A concentrations were measured. The groups had similar duration of anaesthesia and exposure to anaesthetic agents. The area under the curve of concentration (mean, SD) of compound A in the low-flow sevoflurane group (359.8, 106.1 ppm.h) was greater than that in the high-flow sevoflurane group (61.1, 29.3 ppm.h; P<0.01). All groups showed normal plasma creatinine and creatinine clearance, and transient postoperative increases in plasma alanine aminotransferase and alpha glutathione-S-transferase, as well as urinary glucose and alpha glutathione-S-transferase, with no significant differences between groups. There were no significant relationships between the area under the curve of concentration of compound A and the biomarkers. These findings suggest that prolonged anaesthesia with low-flow sevoflurane has similar effects on hepatorenal function to prolonged anaesthesia with high-flow sevoflurane and low-flow isoflurane.
Compound A is one of the degradation products resulting from alkaline dehydrofluorination of sevoflurane, in the presence of carbon dioxide absorbents with strong bases such as potassium and sodium hydroxide 1 . Factors known to be involved with higher levels of compound A are higher sevoflurane concentration 1 , higher carbon dioxide production 2 , higher absorbent temperature 3 , lower fresh gas flow rate 4 , fresh and dry carbon dioxide absorbent 5 and stronger bases in the absorbent 6 . Exposure to compound A may be greater under prolonged anaesthesia with low-flow sevoflurane (LFS) than with high-flow sevoflurane (HFS) and low-flow isoflurane (LFI) and compound A is reported to cause hepatic and renal toxicity in rats 7, 8 . It is possible that increased exposure to compound A in humans may also result in hepatic and renal toxicity. Although LFS has not been shown to have adverse effects in humans, there are few investigations of the potential link between prolonged LFS, compound A and hepatorenal dysfunction in surgical patients. Low-flow inhalational anaesthesia has advantages such as lower cost and reduced release of vaporized anaesthetic into the environment. It is important to validate the safety of LFS, so the purpose of this study was to investigate the effects of prolonged LFS anaesthesia on hepatorenal function in comparison with that of HFS and LFI anaesthesia, using sensitive biomarkers.
MATERIALS AND METHODS Patients
After obtaining the approval of our institutional ethical committee and written informed consent, ASA physical status 1 or 2 patients, scheduled for elective orthopaedic surgery, were enlisted. The surgical procedures were vascularized free-flap transplantations in all patients, with the exception of one patient in the LFS group who underwent plasty of the cervical dura mater. Patients with preoperative hepatorenal dysfunction were excluded. Hepatic dysfunction was defined as a condition in which the upper normal limit of aspartate aminotransferase (AST) (40 IU/l) or alanine aminotransferase (ALT) (45 IU/l) was exceeded or liver disease had been diagnosed. Renal dysfunction was defined as biochemistry exceeding upper normal limit of plasma creatinine (1.2 mg/dl) or blood urea nitrogen (20 mg/dl), or below the lower normal limit of creatinine clearance (70 ml/min), or known renal disease. Twenty-five patients were randomly assigned to one of three groups to receive LFS (n=9), HFS (n=7), or LFI (n=9) anaesthesia for at least 10 hours.
Intramuscular atropine (0.006-0.01 mg/kg) and hydroxyzine (25 or 50 mg) were given 30 minutes before the induction of anaesthesia. In the operating room a venous catheter was inserted into a peripheral vein, and routine monitoring, including electrocardiography, pulse oximetry, and blood pressure, was commenced. A radial arterial line was secured to record mean arterial pressure (MAP) and obtain blood samples. General anaesthesia was induced with 3 to 4 µg/kg of fentanyl and 2 to 2.5 mg/kg of propofol intravenously using a fresh gas flow rate of 5 l/min of oxygen. Intravenous vecuronium 0.1-0.15 mg/kg was used to facilitate tracheal intubation. Anaesthesia was maintained with sevoflurane or isoflurane at a fresh gas flow rate of 5 l/min (2 l/min of oxygen and 3 l/min of air). Thirty minutes after tracheal intubation, both the LFS and LFI groups received 0.5 l/min of air and 0.5 l/min of oxygen at a fresh gas flow rate of 1 l/min, but the HFS group was maintained at 5 l/min. Anaesthesia was titrated to keep MAP within 80-120% of preanaesthetic values, by adjusting the inspired volatile anaesthetic concentration and giving intermittent fentanyl if necessary. The patients were ventilated mechanically at 10-12 ml/kg tidal volume, with the ventilatory rate adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg. Aminoglycoside antibiotics were not used during or after surgery.
Apparatus and measurements
The anaesthetic machine was a North American Dräger IIb (Telford, Pennsylvania, U.S.A.) equipped with 19.2 Dräger vaporizer. Fresh soda lime (Wakolime, Wako Chemical, Osaka, Japan) was used as the carbon dioxide absorbent. In the two-layered soda lime canister, temperature was measured at a point 5 cm from the bottom in the middle of the upper canister and recorded at 15-minute intervals. The concentrations of end-tidal anaesthetic agent, oxygen and carbon dioxide were also measured every 15 minutes using a patient monitor (AS/3, Datex, Finland). In the LFS and HFS groups, gas samples were obtained from the inspiratory limb to determine inspiratory compound A concentration by gas chromatography at 15, 30, and 60 minutes after tracheal intubation, and every 60 minutes thereafter. Blood samples were obtained before, during (10 hours after induction) and on postoperative days 1, 3, and 7. Urine was collected 24 hours before and after anaesthesia, and 10 hours after induction of anaesthesia. No drugs affecting urine output (such as dopamine or aminophylline) were given.
Plasma concentrations of AST, ALT, blood urea nitrogen and creatinine, and urine creatinine, were measured using a Dri-chem 5500® (Fuji Film, Tokyo, Japan). Blood concentrations of glucose, lactate, and urine glucose were measured by YSI 2300 Analyzer (Yellow Springs Instrument, Ohio, U.S.A.), with the lowest detectable level of lactate 0.001 mmol/l and glucose 0.01 mg/dl. Plasma concentrations of α glutathione-S-transferase (GST), urine αGST, and urine πGST were quantified using a Biotrin HEPKIT-Alpha ®, Biotrin NEPHKIT-Alpha®, and Biotrin NEPHKIT-Pi ® , respectively, based on an enzyme linked immunosorbent assay (Biotrin International, Dublin, Ireland). Urinary protein was measured qualitatively, with the lowest level of detection 30 mg/dl. We measured urine volume to determine creatinine clearance, as well as the amount of urinary excretion of glucose, αGST, and πGST. When patients in the LFS group showed abnormal values for the excretion of urine αGST from postoperative days 5 to 7, follow up examinations were used to determine hepatorenal function until postoperative days 14 or 21.
Gas chromatography
A gas chromatograph was used and calibrated by vaporized standard compound A. In brief, a standard compound A solution of 217 ppm was supplied by Maruishi Pharmaceutical (Osaka, Japan). We vaporized 50, 100, and 200 µl of the compound A solution in 695 ml glass bottles, extracted 1 ml from each, and injected it into a gas chromatograph equipped with flame ionization detection (5890 Series II, Hewlett-Packard, Palo Alto, California, U.S.A.). Gas analyses were all performed with this chromatograph. The temperature of the injector and detector was held at 200°C. With respect to the oven temperature, the initial value was 45°C, with an initial time of 2 minutes and an increasing rate of 10°C/min. Preoperatively, we obtained a linear calibration curve (r 2 =0.997) between 3 and 48 ppm. To measure compound A concentration, 1 ml gas samples were obtained from the anaesthetic circuit and injected into the gas chromatograph.
Statistical analysis
Exposure to volatile anaesthetics was calculated as the product of end-tidal concentration and duration of exposure, measured at 15-minute intervals. Total anaesthetic exposure was expressed as the minimum alveolar concentration (MAC) multiplied by hour (MAC.h). We assumed 2.05% 9 and 1.15% 10 as 1 MAC for sevoflurane and isoflurane, respectively. The area under the curve of concentration (AUC) of compound A was determined using a trapezoidal method. Values are expressed as mean (SD) or the number of patients.
For intra-group comparisons, repeated measures of ANOVA were used and Dunnett's multiple comparison test was used as a post hoc test for comparison with pre-anaesthetic values. Differences in exposure to compound A between the LFS and HFS groups were compared using an unpaired t-test. Gender, surgical procedure, and antibiotics were compared using a goodness-of-fit test for chi square among the three groups. One-way ANOVA was used for patient characteristics, anaesthesia management, and laboratory data among the groups and Scheffé's test was used as a post hoc test for comparison between two groups. Relationships between the AUC of compound A and exposure to sevoflurane or biomarkers were evaluated by linear regression analysis. Analyses were performed on the logarithms of plasma AST, plasma ALT, plasma αGST, urine glucose, urine αGST, and urine πGST to improve normality. The P values less than 0.05 were considered significant. Scheffé's test was applied with an α of 0.0167. The sample size was obtained from a previous study 11 . The primary variables were urine glucose and αGST and the sample sizes were based on a one-tailed test of 2-sample lognormal equal variance with a significance level of 0.05, a power level of 0.80, and coefficient of variation of 2. The required sample size of urine glucose and of αGST was nine in both LFS and HFS groups. For plasma ALT, based on a one-tailed test of 2-sample normal distribution equal variance at a significance level of 0.05 and power of 0.80, the required sample size was 26 per group.
RESULTS
The groups were similar with respect to gender, age, height, weight, anaesthesia duration and anaesthetic exposure ( Table 1 ). The three groups were also similar for MAP and blood loss during surgery and for antibiotics used. The maximum concentration of compound A in the LFS group [mean (SD); 38.9 (11.3), range; 23.7-54.0 ppm] was significantly higher than that in the HFS group Table 2) . Blood glucose increased postoperatively in all groups, but did not exceed 200 mg/dl in any patient. There were no significant differences with respect to hepatic biomarkers, either during or after anaesthesia. There were no relationships found between the AUC of compound A and the maximum plasma concentrations of AST (P=0.450), ALT (P=0.641), or αGST (P=0.344). Blood urea nitrogen decreased significantly in all groups but was normal by postoperative day 7 (Table  3) . Plasma creatinine and creatinine clearance remained within the normal range in all groups (Table  3) , however, the urinary excretion of glucose increased significantly until resolution to normal by postoperative day 5 ( Figure 5 ). The urinary excretion of αGST increased transiently above the normal range in all groups ( Figure 6 showed positive urinary protein. There was no relationship between the area under the curve of concentration of inspired compound A and the maximum excretion of urinary glucose (P=0.461), αGST (P=0.611), or πGST (P=0.062). Many patients had abnormal, albeit subclinical, hepatorenal function postoperatively but all were discharged without any adverse effects.
DISCUSSION
Nephrotoxicity due to compound A is characterized by renal tubular necrosis of the cortico-medullary regions in rats, as evidenced by abnormal increases in urinary glucose, protein, albumin, and tubular enzymes including N-acetyl-βglucosaminidase, GST, alanine aminopeptidase, serum creatinine, and blood urea nitrogen 12 . Compound A exposurerelated nephrotoxicity was observed in rats 7, 8, 12 , and has been investigated in surgical patients [13] [14] [15] [16] and healthy volunteers 11, 17, 18 . In those studies, exposure to compound A was assessed using area under the curve of concentration in the inspired gas, and averages of 79 13 , 165 14 , 192 15 , 277 16 , 80 17 , 253 11 commonly used to assess hepatic function [13] [14] [15] [16] [17] [18] , however plasma αGST is rarely used as a sensitive biochemical marker. Some investigations measured urinary αGST excretion as an assessment of renal function 11, 17, 18 in volunteers, although it was not an effective measure in surgical patients [14] [15] [16] . Exposure to compound A in our patients was higher than that reported in previous clinical studies of surgical patients [13] [14] [15] [16] and healthy volunteers 17, 18 .
Hepatic dysfunction and injury
We measured AST, ALT, and αGST as biochemical markers of hepatic function. Anaesthetic-related hepatic toxicity is invariably cytotoxic rather than cholestatic, and the most sensitive and specific biomarkers for its assessment in humans are serum AST and ALT. These enzymes are located in hepatocytes, with periportal distribution greater than centrilobular 19 . In contrast, αGST is uniformly distributed in both centrilobular and periportal hepatocytes 20 and because centrilobular hepatocytes are very susceptible to damage, αGST may be a sensitive marker of anaesthetic related hepatic injury.
We found that prolonged anaesthesia with LFS, HFS, or LFI was associated with transiently increased plasma levels of AST, ALT, and αGST postoperatively, and that those patients with elevated plasma αGST also had an abnormal elevation of plasma ALT. Eger and coworkers 18 suggested possible hepatotoxicity due to compound A. However, several investigations have shown that prolonged LFS anaesthesia does not induce hepatic dysfunction or injury 15, 17 , nor does it induce it to the same degree as other anaesthetic agents 13, 14, 16 . Nishiyama 21 reported that patients who received isoflurane anaesthesia had elevated hepatic enzymes more frequently than those who received sevoflurane: however, the present results did not show such a difference. Isoflurane is metabolized at a rate of approximately 0.2% and the metabolite binds to hepatic protein to yield metabolite-modified 215 proteins. In contrast, sevoflurane is not metabolized in such a way and immune-based hepatitis after sevoflurane has not been reported.
HEPATORENAL EFFECTS OF LOW-FLOW SEVOFLURANE
We observed the highest levels of ALT and αGST on postoperative day 7, which is consistent with LFS studies by Kharasch 14 and Obata 16 . Elevated ALT and αGST returned to normal by postoperative day 14-21, so we consider that it might take two to three weeks to restore hepatic function after anaesthesia exceeding ten hours.
Almost all patients showed increased plasma levels of lactate intraoperatively, regardless of the anaesthetic employed. Anaesthetic conditions were assumed to be aerobic in all our patients because no hypoxaemia or excessive hypotension occurred. All patients received acetate but not lactate in their intravenous fluid, so we do not believe this fluid contributed to the increase in lactate we observed. Thoracic or abdominal surgery lasting at least three hours does not readily produce abnormal lactate levels 22 , but it is thought that surgical stress may induce lactate metabolism, especially in the liver. present results, although inconsistent with the previous study 22 , suggest that prolonged surgery and/or anaesthesia increases plasma lactate levels, possibly indicating transiently abnormal cellular metabolism.
Renal dysfunction and injury
Creatinine clearance remains the gold standard for assessing renal function and predicting the onset of perioperative renal dysfunction 23 . αGST and πGST are confined mainly to the proximal and distal tubules of the human kidney respectively 24 , and the abnormal excretion in urine of these site-specific tubular cell enzymes is associated with tubular injury 25 . Kharasch 13 pointed out that increased urinary excretion of glucose and αGST were better monitors of the effects of sevoflurane and/or compound A on renal function in humans than blood urea nitrogen and serum creatinine.
No renal dysfunction was observed in any of our patients during anaesthesia, while urinary excretion of glucose and αGST increased postoperatively without changes in plasma creatinine or blood urea nitrogen or a decrease in creatinine clearance. Consistent with the report of Kharasch 14 , even one patient exposed to a high level of compound A (563 ppm.h) did not have renal dysfunction postoperatively.
An increase in urinary glucose indicates re-absorption insufficiency in the proximal tubules, while increase in αGST excretion suggests lysosomal damage. However, it is still uncertain whether increased urinary αGST is indicative of renal tubular necrosis in humans. In this study, the elevated excretion of urinary αGST in the LFS group resolved by postoperative day 14 and although no further evaluation was performed in the other groups, there was a very low likelihood of dysfunction. Higuchi 15 reported that some patients who received LFS showed increases in urinary glucose, whereas there was no such increase in those who received LFI or HFS. This result is different from the present study, possibly because their AUC of compound A [192.1 (45.6) ppm.h] and duration of anaesthesia [400 (114) minutes] were both lower. Their methodology was also different, as an oxidase-peroxidase method with a minimum detectable level of 50 mg/dl was used for glucose measurement. Goldberg 11 reported that the urinary excretion of glucose and αGST increased eight hours after exposure to sevoflurane at a fresh gas flow rate of 2 l/min in 11 volunteers. Further, urinary glucose and αGST on day 3 showed average values of 0.778 g/24 h and 146.56 µg/24 h, respectively. In our study urinary glucose and αGST increased significantly in the LFS group, with average values of 0.628 g/24 h and 78.26 µg/24 h on postoperative day 3, respectively. The average exposure to compound A and sevoflurane in the Goldberg study was 253 ppm.h and 11.7 MAC.h respectively. Althought the exposure to compound A in the Goldberg study was less than in ours, the urinary excretion of glucose was similar and αGST was greater. These findings suggest that increases in the urinary excretion of glucose and αGST are not dependent on exposure to compound A. However, it is not certain that an abnormal level of urinary excretion is dependent on exposure to sevoflurane, because Goldberg's subjects were volunteers, not surgical patients.
Although compound A exposure-related nephrotoxicity has been observed in rats 7, 8, 12 , it has not been reported in humans. Kharasch suggested that renal injury results from the metabolism of compound A via the β-lyase pathway to a reactive thiol. The threshold for compound A-induced nephrotoxicity in humans may be much higher than that in rats 14 , as evidenced by findings of renal β-lyase activity and β-lyase metabolism associated with compound A-cysteine conjugates in vitro 26 and the relative metabolic flux of compound A through its detoxification pathway in vivo 27 . Such metabolic differences might account for why we did not find evidence of compound A exposure-related renal dysfunction in the present study, and we suggest compound A is unlikely to play a significant role in renal dysfunction or injury after prolonged sevoflurane anaesthesia in surgical patients.
Some studies 11, [16] [17] [18] reported abnormal increases in excretion of urine albumin after LFS anaesthesia, postulated to be a result of greater exposure to compound A. However, no patient in this study showed positive findings in the urinary protein test. Our urinary protein test was not quantitative, but qualitative. Urine output was high in all patients [range 2340-4260 ml/day], so we may have been unable to detect urinary protein.
Limitations
There were several limitations to this study. Firstly, the sample size was small, raising the possibility of type II error. The small number reflects the difficulty in recruiting cases of long duration but minimal surgical effect within a single institute, using a complex study design. Secondly, the participants were surgical patients who experienced surgical injury and received other clinically relevant treatments including drugs, infusions, and antibiotics which may have affected postoperative hepatorenal function. Several kinds of antibiotics are known to be harmful post-operatively, although we excluded nephrotoxic aminoglycosides. Thirdly, our subjects were young healthy patients, so the results may not be applicable to older patients with less hepatorenal reserve, or to patients with impaired hepatorenal function preoperatively.
In conclusion, surgical patients who received prolonged low-flow sevoflurane, high-flow sevoflurane, or low-flow isoflurane anaesthesia showed evidence of transient hepatorenal dysfunction postoperatively, but these were mild, subclinical abnormalities. It is unlikely that Compound A played a significant role, because there were no relationships between the area under the curve of inspiratory compound A and the biochemical markers of hepatorenal function. Although the degradation product compound A can be generated at high levels during prolonged sevoflurane anaesthesia when fresh gas flows are set at a low rate, we conclude that prolonged anaesthesia with low-flow sevoflurane has similar effects on hepatorenal function as prolonged anaesthesia with high-flow sevoflurane or low-flow isoflurane.
